Obesity medications drive shifts in health, insurance, and social consumption

The widespread use of obesity and diabetes medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), is driving significant physiological, social, and economic shifts.

Medically, users report side effects including dry mouth, halitosis, and gastrointestinal issues like nausea and acid reflux, which can impact dental health. There are also emerging discussions regarding reproductive health; rapid weight loss can restore ovulation in some women, but delayed gastric emptying may reduce the efficacy of oral contraceptives, leading to unplanned pregnancies. Experts advise using barrier methods during treatment.

Economically, the insurtech sector is monitoring how increased longevity and reduced mortality rates from these treatments might influence life insurance pricing and risk assessment. Socially, the reduced appetite associated with these drugs is prompting changes in large-scale food and beverage events, such as Oktoberfests, as organizers adapt to consumers who consume less food and alcohol.